drugset / Trial / NCT00108264

Tumor RNA Transfected Dendritic Cell Vaccines

NCT00108264 ↗

Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to use dendritic cells transfected with amplified RNA from autologous tumor cells to develop a vaccine strategy for the treatment of prostate cancer in patients with disseminated disease.

Timeline

Start
—
Primary completion
—
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tumor RNA transfected dendritic cells Cell therapy — —

Indications